<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00908531</url>
  </required_header>
  <id_info>
    <org_study_id>DBCG 07-REAL</org_study_id>
    <nct_id>NCT00908531</nct_id>
  </id_info>
  <brief_title>Trial of Endocrine Against Locoregional Therapy First in Postmenopausal Women With Early Breast Cancer</brief_title>
  <acronym>REAL</acronym>
  <official_title>Randomized Trial of Endocrine Therapy Against Locoregional Therapy First. A DBCG Trial in Postmenopausal Patients With Operable Hormone Receptor Positive Tumors Larger Than 2 cm.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Breast Cancer Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Danish Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Danish Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Danish Breast Cancer Cooperative Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis to be addressed in this randomized phase III trial is that 4 months of
      letrozole may be superior to surgery as primary therapy for early stage hormone receptor
      positive breast cancer in postmenopausal women, provided that these patients will receive
      definitive and radical surgery and adjuvant therapies as otherwise indicated at the
      completion of preoperative letrozole.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor recruitement
  </why_stopped>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Invasive disease-free survival</measure>
    <time_frame>2020</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2020</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant recurrence-free survival</measure>
    <time_frame>2020</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete pathological response</measure>
    <time_frame>2014</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Miller-Payne Score</measure>
    <time_frame>2014</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical tumour response</measure>
    <time_frame>2014</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mammographic response</measure>
    <time_frame>2014</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">123</enrollment>
  <condition>Operable Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Postoperative letrozole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Definitive surgery without preoperative AI treatment followed post-operatively by 5 AI for years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Preoperative letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with letrozole for 4 months before definitive surgery. Post-operatively patients with responsive or stationary tumors continue letrozole to a total of 5 years. Patients with endocrine resistant tumors are re-considered for chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>letrozole (Femara)</intervention_name>
    <description>tablet 2.5 mg daily</description>
    <arm_group_label>Postoperative letrozole</arm_group_label>
    <arm_group_label>Preoperative letrozole</arm_group_label>
    <other_name>Femara</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  Age 60 years or older

          -  Measurable non-metastatic and non-inflammatory breast cancer

          -  Tumor of 2 cm or larger

          -  ER and/or PgR positive tumor

          -  Co-morbidity index 0 - 3, e.g., no other serious medical condition

        Exclusion Criteria:

          -  Prior medical therapy for a malignant disease, including aromatase inhibitors

          -  Distant metastasis

          -  Need for chemotherapy

          -  Past or current history of other neoplasms (except for curative treated basal skin
             cancer or in situ carcinoma of the cervix uteri)

          -  Treatment with a non-approved drug within 30 days
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bent Ejlertsen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>DBCG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of Breast Surgery; Aalborg Sygehus</name>
      <address>
        <city>Aalborg</city>
        <zip>DK-9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Breast Surgery; Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Surgery; Sydvestjysk Sygehus Esbjerg</name>
      <address>
        <city>Esbjerg</city>
        <zip>DK-6700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Breast Surgery; Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>DK-2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Oncology; Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>DK-5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Depart. of Breast Surgery, Ringsted Sygehus</name>
      <address>
        <city>Ringsted</city>
        <zip>4100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Breast Surgery; Vejle Sygehus</name>
      <address>
        <city>Vejle</city>
        <zip>DK-7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Breast Surgery; Regionshospitalet Viborg</name>
      <address>
        <city>Viborg</city>
        <zip>DK-8800</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Surgery; Århus Sygehus</name>
      <address>
        <city>Århus</city>
        <zip>DK-8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2009</study_first_submitted>
  <study_first_submitted_qc>May 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2009</study_first_posted>
  <last_update_submitted>February 13, 2015</last_update_submitted>
  <last_update_submitted_qc>February 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Danish Breast Cancer Cooperative Group</investigator_affiliation>
    <investigator_full_name>Bent Ejlertsen</investigator_full_name>
    <investigator_title>Professor, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Breast neoplasms</keyword>
  <keyword>Randomised trial</keyword>
  <keyword>Aromatase Inhibitors</keyword>
  <keyword>Preoperative care</keyword>
  <keyword>Age 60 or older</keyword>
  <keyword>Hormone receptor positive tumor</keyword>
  <keyword>Tumor lager than 2 cm</keyword>
  <keyword>No distant metastasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

